- Home
- MFP vs VRDN Comparison
MFP vs VRDN Comparison
Compare MFP & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
SELL
Current Price
$39.33
SELL
Current Price
$18.45
Company Overview
Basic Information| Metric | MFP | VRDN |
|---|---|---|
| Founded | 2025 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Medical Specialities |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 2.1B |
| IPO Year | 2025 | 2014 |
Fundamental Metrics
Financial Performance| Metric | MFP | VRDN |
|---|---|---|
| Price | $39.33 | $18.45 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 17 |
| Target Price | ★ $46.67 | $36.75 |
| AVG Volume (30 Days) | 425.7K | ★ 1.9M |
| Earning Date | 11-13-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $5,706,000.00 |
| Revenue This Year | $11.53 | N/A |
| Revenue Next Year | $5.59 | $681.16 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $38.51 | $13.18 |
| 52 Week High | $52.58 | $34.29 |
Technical Indicators
Market Signals| Indicator | MFP | VRDN |
|---|---|---|
| Relative Strength Index (RSI) | 37.67 | 34.41 |
| Support Level | N/A | $17.54 |
| Resistance Level | $43.70 | $20.05 |
| Average True Range (ATR) | 1.59 | 0.80 |
| MACD | -0.17 | -0.11 |
| Stochastic Oscillator | 14.39 | 23.72 |
Price Performance
Historical Comparison MFP
VRDN
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.